Printer Friendly

MATTHEW D. HAINES JOINS CEL-SCI CORPORATION AS DIRECTOR OF INVESTOR RELATIONS

 ALEXANDRIA, Va., July 7 /PRNewswire/ -- CEL-SCI Corporation (NASDAQ-NMS: CELI) announced today that Matthew D. Haines has joined the company in the newly created position of director of investor relations.
 Haines' primary responsibilities are to further develop and expand the company's strategic communications and investor relations programs. He is reporting to Geert Kersten, chief operating officer.
 "We are extremely pleased to have Matt Haines join us as we accelerate our product development programs and corporate expansion," commented Kersten. "His experience and expertise in investor relations and media relations will be highly valuable in communicating our progress in AIDS and cancer treatment and in building shareholder value."
 Prior to joining CEL-SCI, Haines was an investor relations and media relations consultant to numerous biotechnology companies, including CEL- SCI. His achievements included developing and implementing investor relations and media relations campaigns which were instrumental in increasing investor awareness and raising additional capital.
 His communications experience includes account management positions with several New York-based financial public relations firms, including Strategic Growth International, Inc., Cameron Associates and Georgeson & Company, Inc., where he counseled clients in a diverse range of industries. Haines, 39, earned a master's degree in business administration from New York University in 1985.
 CEL-SCI Corporation has pioneered the development of natural cytokine mixtures ("cocktails") for the treatment of cancers and other immune deficiency diseases. Its 50 percent owned subsidiary, Viral Technologies, Inc., Bethesda, Md., is developing the HGP-30 AIDS Vaccine, based upon a highly conserved segment of the p17 core protein of the AIDS virus.
 -0- 7/7/93
 /CONTACT: Geert Kersten, chief operating officer, 703-549-5293, or Matthew Haines, director of investor relations, 212-996-0608, both of CEL-SCI/
 (CELI)


CO: CEL-SCI Corporation ST: Virginia IN: MTC SU: PER

DC-MH -- DC002 -- 8937 07/07/93 08:58 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 7, 1993
Words:292
Previous Article:FOOD LION, INC. DECLARES DIVIDEND
Next Article:VOLKSWAGEN RELEASES ALL-NEW GOLF AND JETTA IN NORTHWEST
Topics:


Related Articles
CEL-SCI NAMES DR. EVAN M. HERSH TO ITS SCIENTIFIC ADVISORY BOARD
CEL-SCI CORPORATION ANNOUNCES ADDITION OF NEW MEMBER TO ITS SCIENTIFIC ADVISORY BOARD
CEL-SCI WINS FINAL ROUND IN EUROPEAN PATENT LITIGATION
CEL-SCI ENTERS PROCESS DEVELOPMENT AGREEMENT WITH ROGER WILLIAMS MEDICAL CENTER
CEL-SCI CORPORATION ANNOUNCES ESTABLISHMENT OF PRODUCTION FACILITY
CEL-SCI CORPORATION ANNOUNCES THE ADDITION OF A NEW MEMBER TO ITS SCIENTIFIC ADVISORY BOARD
CEL-SCI CORPORATION RESPONDS TO BROKER INQUIRIES REGARDING TRADING ACTIVITY IN CEL-SCI SHARES
CEL-SCI Receives Funds From Strategic Partner Investment.
CEL-SCI Signs Strategic Partner Agreement.
CEL-SCI Corporation Announces 2005 Financial Results.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters